TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 North America Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 North America Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 North America Non-Alcoholic Steatohepatitis Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. North America Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market– North America Analysis
6.1 North America Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
7. North America Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.3.1 Overview
7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
7.4 Ocaliva
7.4.1 Overview
7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)
7.5 Elafibranor
7.5.1 Overview
7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)
7.6 Selonsertib & Cenicriviroc
7.6.1 Overview
7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)
8. North America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.3.1 Overview
8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diagnosis
8.4.1 Overview
8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
9. North America Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Online Provider
9.5.1 Overview
9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
10. North America Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis
10.1 North America: Non-Alcoholic Steatohepatitis Market
10.1.1 Overview
10.1.3 North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
10.1.3.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.1.2 US: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.3.1.3 US: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.3.1.4 US: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
10.1.3.2 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.1 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.2.2 Canada: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.3.2.3 Canada: Non-Alcoholic Steatohepatitis Market, by Application , 2019–2028 (US$ Million)
10.1.3.2.4 Canada: Non-Alcoholic Steatohepatitis Market, by Sales Channel , 2019–2028 (US$ Million)
10.1.3.3 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.1 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3.3.2 Mexico: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.3.3.3 Mexico: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.3.3.4 Mexico: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Cadila Pharmaceuticals Ltd.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Intercept Pharmaceuticals, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novartis AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Galmed Pharmaceuticals.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GENFIT.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Prometheus Laboratories
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Siemens Healthineers AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Laboratory Corporation of America Holdings
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms